| Identification | More | [Name]
Dorzolomide hydrochloride | [CAS]
130693-82-2 | [Synonyms]
(2s,4s)-2-ethylamino-4-methyl-5,5-dioxo-5,7-dithiabicyclo[4.3.0]nona-8,10-diene-8-sulfonamide hydrochloride
DORZOLAMIDE HCL
DORZOLAMIDE HYDROCHLORIDE
dorzolomide hydrochloride
3-b)thiopyran-2-sulfonamide,5,6-dihydro-4-(ethylamino)-6-methyl-4h-thieno(
mk-0507
monohydrochloride,(4s-trans)-7-dioxide
DorzolomideHcl,Usp
DORZOLAMIDEHYDROCHLORIDE(SUBJECTTOPATENTFREE)
(S,S)-(-)-5,6-Dihydro-4-ethylamino-6-methyl-4H-thieno[2,3-b]thiopyran-2-sulfonamide-7,7-dioxide monohydrochloride
4H-Thieno[2,3-b]thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-, 7,7-dioxide, monohydrochloride, (4S,6S)-
4H-Thieno[2,3-b]thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-, 7,7-dioxide, monohydrochloride, (4S-trans)-
L 671152
MK 507
Trusopt
Dorzolamide HCI
4H-Thieno[2,3-b]thiopyran-2-sulfonamide, 4-(ethylamino)-5,
6-dihydro-6-methyl-, 7,7-dioxide, monohydrochloride, (4S,6S)
(2S,4S)-2-Ethylamino-4-methyl-5,5-dioxo-5,7-dithiabicyclo[4.3.0]nona-8,10-diene-8-sulfonamide hydrochloride
(4S,6S)-4-(Ethylamino)-5,6-dihydro-6-methyl-4H-thieno[2,3-β]thiopyran-2-sulfonamide 7,7-Dioxide Hydrochloride
Dorzalamide | [EINECS(EC#)]
620-304-2 | [Molecular Formula]
C10H17ClN2O4S3 | [MDL Number]
MFCD00884659 | [Molecular Weight]
360.9 | [MOL File]
130693-82-2.mol |
| Chemical Properties | Back Directory | [Appearance]
White Powder | [Melting point ]
265-2670C | [alpha ]
D24 -8.34° (c = 1 in methanol) | [storage temp. ]
Keep in dark place,Inert atmosphere,2-8°C | [solubility ]
Soluble in water, slightly soluble in methanol, very slightly soluble in anhydrous ethanol. | [form ]
neat | [color ]
White to Off-White | [Usage]
Carbonic anhydrase inhibitor. Antiglaucoma agent. | [λmax]
254nm(CHCl3:MeOH= aq.)(lit.) | [Merck ]
14,3426 | [BRN ]
5896026 | [CAS DataBase Reference]
130693-82-2(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Description]
Dorzolamide hydrochloride was introduced in the U.S.A. as eye drops
for the treatment of open-angle glaucoma and ocular hypertension. Dorzolamide is a
potent carbonic anhydrase inhibitor that, on topical administration, lowers intraocular
pressure (IOP). In a clinical study in patients with bilateral primary open-angle
glaucoma or ocular hypertension, dorzolamide (0.7-2%) was found to significantly lower
IOP throughout the day. Dorzolamide has been shown to be effective as a single
therapy or in combination with β-blockers. | [Chemical Properties]
White Powder | [Originator]
Merck (U.S.A.) | [Uses]
An inhibitor of carbonic anhydrase. | [Uses]
analgesic | [Uses]
Antiglaucoma drug;Carbonic anhydrase inhibitor | [Uses]
Carbonic anhydrase inhibitor. Antiglaucoma agent. | [Uses]
Dorzolamide HCl Ophthalmic Solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. | [Definition]
ChEBI: The hydrochloride salt of dorzolamide. It is used in ophthalmic solutions to lower increased intraocular pressure in the treatment of open-angle glaucoma and ocular hypertension. | [Manufacturing Process]
Manufacturing process for Dorzolamide hydrochloride includes these steps as follows: Step A: Sulfuric Acid Ritter Procedure;Step B: Sulfonylation Procedure Step C: Chlorosulfonylation Procedure;Step D: Amidation Procedure;Step E: Reduction via Borane Generated in situ Procedure;Step F: Maleate Salt Formation Procedure;Step G: Crude Hydrochloride Salt Formation;Step H: Recrystallization Procedure. | [Brand name]
Trusopt (Merck). | [Therapeutic Function]
Antiglaucoma | [Veterinary Drugs and Treatments]
Dorzolamide is often used in the contralateral eye of a dog with
primary glaucoma to prevent development of bilateral disease. It
is also an excellent agent to consider for most secondary glaucomas
in dogs and cats because it has no effect on pupil size. Like the
related oral carbonic anhydrase inhibitors (dichlorphenamide or
Daranide?, methazolamide or Neptazane?), dorzolamide decreases
aqueous humor production by the ciliary body epithelium by altering
pH and affecting the H+/Na+ active transport exchange mechanism.
Oral carbonic anhydrase inhibitors cause numerous systemic
side effects such as metabolic acidosis and panting, diarrhea, vomiting,
anorexia and others, all of which can be avoided with topical
carbonic anhydrase inhibitors. |
|
|